HIMS & HERS HEALTH INC (HIMS)
US4330001060 - Common Stock
Taking everything into account, HIMS scores 5 out of 10 in our fundamental rating. HIMS was compared to 113 industry peers in the Health Care Providers & Services industry. HIMS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. HIMS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year HIMS was profitable.
HIMS had a positive operating cash flow in the past year.
HIMS had negative earnings in 4 of the past 5 years.
HIMS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of HIMS (16.81%) is better than 98.23% of its industry peers.
With an excellent Return On Equity value of 23.01%, HIMS belongs to the best of the industry, outperforming 92.92% of the companies in the same industry.
With a decent Return On Invested Capital value of 7.89%, HIMS is doing good in the industry, outperforming 78.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.81% | ||
| ROE | 23.01% | ||
| ROIC | 7.89% |
ROA(3y)-16.29%
ROA(5y)-9.96%
ROE(3y)-20.03%
ROE(5y)-12.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HIMS has a Profit Margin of 8.15%. This is amongst the best in the industry. HIMS outperforms 90.27% of its industry peers.
HIMS has a Operating Margin (3.62%) which is in line with its industry peers.
HIMS's Gross Margin of 81.13% is amongst the best of the industry. HIMS outperforms 93.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.62% | ||
| PM (TTM) | 8.15% | ||
| GM | 81.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HIMS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for HIMS has been increased compared to 1 year ago.
There is no outstanding debt for HIMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
HIMS has an Altman-Z score of 19.64. This indicates that HIMS is financially healthy and has little risk of bankruptcy at the moment.
HIMS's Altman-Z score of 19.64 is amongst the best of the industry. HIMS outperforms 97.35% of its industry peers.
There is no outstanding debt for HIMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.64 |
ROIC/WACC0.87
WACC9.03%
2.3 Liquidity
A Current Ratio of 2.14 indicates that HIMS has no problem at all paying its short term obligations.
HIMS's Current ratio of 2.14 is fine compared to the rest of the industry. HIMS outperforms 76.11% of its industry peers.
A Quick Ratio of 1.82 indicates that HIMS should not have too much problems paying its short term obligations.
HIMS's Quick ratio of 1.82 is fine compared to the rest of the industry. HIMS outperforms 71.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.14 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
HIMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 358.82%, which is quite impressive.
Looking at the last year, HIMS shows a very strong growth in Revenue. The Revenue has grown by 56.70%.
EPS 1Y (TTM)358.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%900%
Revenue 1Y (TTM)56.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.22%
3.2 Future
HIMS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 71.62% yearly.
The Revenue is expected to grow by 20.08% on average over the next years. This is a very strong growth
EPS Next Y567.75%
EPS Next 2Y149.8%
EPS Next 3Y110.4%
EPS Next 5Y71.62%
Revenue Next Year66.53%
Revenue Next 2Y51.82%
Revenue Next 3Y38.74%
Revenue Next 5Y20.08%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 52.05, HIMS can be considered very expensive at the moment.
HIMS's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 28.65, HIMS is valued quite expensively.
A Price/Forward Earnings ratio of 49.11 indicates a quite expensive valuation of HIMS.
The rest of the industry has a similar Price/Forward Earnings ratio as HIMS.
When comparing the Price/Forward Earnings ratio of HIMS to the average of the S&P500 Index (23.56), we can say HIMS is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.05 | ||
| Fwd PE | 49.11 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HIMS is on the same level as its industry peers.
HIMS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. HIMS is cheaper than 68.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.45 | ||
| EV/EBITDA | 75.41 |
4.3 Compensation for Growth
HIMS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HIMS's earnings are expected to grow with 110.40% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y149.8%
EPS Next 3Y110.4%
5. Dividend
5.1 Amount
HIMS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HIMS & HERS HEALTH INC
NYSE:HIMS (11/21/2024, 11:13:08 AM)
22.9041
+1.11 (+5.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.00B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.05 | ||
| Fwd PE | 49.11 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.09
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.81% | ||
| ROE | 23.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 3.62% | ||
| PM (TTM) | 8.15% | ||
| GM | 81.13% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.14 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)358.82%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y567.75%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)56.7%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y